Opinion|Videos|August 15, 2024

Treatment Algorithm for Relapsed/Refractory DLBCL

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Carla Casulo, MD

Carla Casulo, MD, and the Oncology Brothers review the treatment algorithm for patients with relapsed/refractory DLBCL.

Episodes in this series

Carla Casulo, MD, with the Oncology Brothers presenting slides

EP. 1 Biopsy Practices in DLBCL

Carla Casulo, MD, with the Oncology Brothers presenting slides

EP. 2 First-Line Treatment of Stage I/II DLBCL

Carla Casulo, MD, with the Oncology Brothers presenting slides

EP. 3 Treatment Practices for Stage III/IV DLBCL

Carla Casulo, MD, with the Oncology Brothers presenting slides

EP. 4 Treatment Algorithm for Relapsed/Refractory DLBCL

Carla Casulo, MD, with the Oncology Brothers presenting slides

EP. 5 Adverse Event Considerations in DLBCL

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Blood cells in a bone marrow biopsy, AI Generative | Image Credit: © Kateryna - stock.adobe.com

October 20th, 2026

Trispecific CAR T Cells Demonstrate Safety, Early Activity in B-Cell Lymphoma

In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Trending on CancerNetwork

Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer

Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer

Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study

ctDNA Clearance Tracks With Survival on Pembrolizumab in HPV-Negative HNSCC

Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC